NCT00486434View on ClinicalTrials.gov

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,176

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Osteoarthritis
Interventions
DRUG

SMC021 Oral Calcitonin

0.8mg SMC021 (Oral Calcitoinin) twice daily

DRUG

SMC021 Placebo

Placebo orally, twice daily

Trial Locations (9)

2750

CCBR Ballerup, Ballerup Municipality

7100

CCBR Vejle, Vejle

9000

CCBR Aalborg, Aalborg

10128

CCBR Estonia, Tallinn

53002

CCBR Czech, Pardubice

Unknown

CCBR Hong Kong, Hong Kong

15-461

Centrum Osteoporozy i Chorób Kostno Stawowych, ul. Waryńskiego 6/2, Bialystok

04703

CCBR Poland, Warsaw

030463

CCBR Romania, Bucharest

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Nordic Bioscience A/S

INDUSTRY

NCT00486434 - Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis | Biotech Hunter | Biotech Hunter